DATROWAY Approved in China for Previously Treated HR+/HER2- Metastatic Breast Cancer
China’s National Medical Products Administration (NMPA) has approved DATROWAY (datopotamab deruxtecan) for the treatment of adults with unresectable or metastatic hormone receptor (HR)…
Read More...
Read More...
